An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma.

MLA

Yunqian Chu, et al. “An Exploratory Clinical Study of β-Glucan Combined with Camrelizumab and SOX Chemotherapy as First-Line Treatment for Advanced Gastric Adenocarcinoma.” Frontiers in Immunology, Sept. 2024, pp. 01–09. EBSCOhost, https://doi.org/10.3389/fimmu.2024.1448485.

APA

Yunqian Chu, Xuan He, Ya Xue, Hua Jiang, Chan Zhu, Chunjian Qi, Xing Zhang, Dongsheng Chen, Hanjue Dai, Qingying Xian, & Wenyu Zhu. (2024). An exploratory clinical study of β-glucan combined with camrelizumab and SOX chemotherapy as first-line treatment for advanced gastric adenocarcinoma. Frontiers in Immunology, 01–09. https://doi.org/10.3389/fimmu.2024.1448485

Chicago

Yunqian Chu, Xuan He, Ya Xue, Hua Jiang, Chan Zhu, Chunjian Qi, Xing Zhang, et al. 2024. “An Exploratory Clinical Study of β-Glucan Combined with Camrelizumab and SOX Chemotherapy as First-Line Treatment for Advanced Gastric Adenocarcinoma.” Frontiers in Immunology, September, 01–09. doi:10.3389/fimmu.2024.1448485.